

# CONTENTS

<b>1</b>	<b>Introduction: viruses, immunity, equations</b>	<b>1</b>
1.1	Viruses	1
1.2	Immunity	3
1.2.1	B cells	3
1.2.2	T cells	4
1.3	Mathematical biology	6
1.4	Further reading	9
<b>2</b>	<b>HIV</b>	<b>10</b>
2.1	Discovery	10
2.2	Some basic facts about HIV	11
2.3	Treatment	13
2.4	Origins of HIV	14
2.5	Further reading	15
<b>3</b>	<b>The basic model of virus dynamics</b>	<b>16</b>
3.1	The model	17
3.2	Dynamics	18
3.3	Equilibrium	21
3.4	The primary phase of HIV and SIV infection	21
3.4.1	Estimating $R_0$	24
3.4.2	Vaccination to reduce $R_0$	25
3.5	Further reading	26
<b>4</b>	<b>Anti-viral drug therapy</b>	<b>27</b>
4.1	Theory	30
4.1.1	HIV: reverse transcriptase inhibitors	30
4.1.2	HIV: protease inhibitors	32
4.1.3	Rise of uninfected cells	34
4.1.4	Long-lived infected cells	34
4.2	Experiment	36
4.2.1	Short-term decay	36
4.2.2	CD4 cell increase	38
4.2.3	Long-lived infected cells	39
4.2.4	Virion turnover	40
4.2.5	Triple-drug therapy	41
4.2.6	Eradication	42
4.3	Further reading	43

<b>5</b>	<b>Dynamics of hepatitis B virus</b>	44
5.1	Theory	45
5.2	Experiment	46
5.3	Comparing HBV and HIV	50
5.4	Further reading	51
<b>6</b>	<b>Dynamics of immune responses</b>	52
6.1	A self-regulating CTL response	53
6.1.1	Persistent infection or clearance	55
6.1.2	Variation in CTL responsiveness leads to a negative correlation between virus load and the magnitude of the CTL response	56
6.2	Other self-regulating immune responses	56
6.3	A nonlinear CTL response: predator–prey dynamics	58
6.3.1	Virus load reduction	59
6.3.2	Variation in immune responsiveness	59
6.4	A linear immune response	61
6.5	Dynamic elimination	63
6.6	The simplest models of immune response dynamics	63
6.6.1	Variation in immune responsiveness	66
6.7	Experimental observations: HTLV-1 and HIV-1, 2	66
6.8	Further reading	67
<b>7</b>	<b>How fast do immune responses eliminate infected cells?</b>	69
7.1	The rate of CTL-mediated lysis <i>in vitro</i>	71
7.2	The dynamics of CTL-mediated lysis	74
7.2.1	Model 1	75
7.2.2	Model 2	76
7.3	Virus decay slopes	77
7.4	Comparing HIV and HBV	80
7.5	Further reading	81
<b>8</b>	<b>What is a quasispecies?</b>	82
8.1	More than atoms in our universe	83
8.2	Quasispecies live in sequence space	84
8.3	Quasispecies explore fitness landscapes	84
8.4	The mathematics of quasispecies	85
8.5	Error-thresholds	86
8.6	Some fancier quasispecies maths	87
8.7	Viral quasispecies	88
8.8	Antigenic escape and optimum mutation rate	89
8.9	Further reading	89

<b>9</b>	<b>The frequency of resistant mutant virus before anti-viral therapy</b>	90
9.1	Wild-type and mutant differ by 1-point mutation	91
9.2	Wild-type and mutant differ by 2-point mutations	92
9.3	Wild-type and mutant differ by $n$ -point mutations	93
9.4	Some practical implications	95
9.5	Further reading	96
<b>10</b>	<b>Emergence of drug resistance</b>	97
10.1	The basic model	100
10.2	Emergence of resistance during drug treatment	101
10.2.1	Equilibrium properties	102
10.2.2	Total gain of CD4 cells and total reduction of virus load are independent of inhibition of sensitive virus	103
10.2.3	A stronger drug selects for faster emergence of resistance	105
10.3	The probability of producing a resistant mutant during therapy	105
10.4	Summary	108
10.5	Further reading	109
<b>11</b>	<b>Timing the emergence of resistance</b>	110
11.1	Theory	110
11.2	Observation	116
11.2.1	The probability of producing replication competent provirus	117
11.3	Summary	121
11.4	Further reading	121
<b>12</b>	<b>Simple antigenic variation</b>	123
12.1	The basic model of antigenic variation	125
12.2	Antigenic variation of HIV: diversity threshold	129
12.3	Three kinds of observed lentivirus infections	133
12.4	Further reading	136
<b>13</b>	<b>Advanced antigenic variation</b>	137
13.1	Immune response can select for or against antigenic diversity	138
13.1.1	Cross-sectional comparisons	142
13.2	Antigenic variation of HIV with different parameter values	143
13.2.1	Cross-sectional comparisons	146
13.3	Comparison with data	147
13.4	Further reading	148
<b>14</b>	<b>Multiple epitopes</b>	149
14.1	Experimental evidence	153
14.2	The simplest multiple epitope model	155

14.3	Different parameters for different mutants	157
14.3.1	What determines immunodominance?	161
14.4	Activated CTLs arise from inactivated precursors	162
14.4.1	The neutral case: all mutants have the same replication rates	163
14.4.2	The mutants have different replication rates	164
14.4.3	The limit of large $\eta$	167
14.5	The $2 \times 1$ case	167
14.5.1	$\eta = 0$	167
14.5.2	$\eta > 0$	169
14.5.3	The limit of large $\eta$	174
14.6	Cross-reactivity within the variants of a given epitope	174
14.7	Immunogenicity and intracellular competition	175
14.8	Immunotherapy	177
14.9	Summary	179
14.10	Further reading	181
<b>15</b>	<b>Everything we know so far and beyond</b>	<b>182</b>
15.1	The mechanism of HIV-1 disease progression	182
15.2	How to overcome HIV	186
15.3	A quantitative immunology and virology	187
15.4	Further reading	187
<b>Appendix A: Dynamics of resistance in different types of infected cells</b>		<b>188</b>
<b>Appendix B: Analysis of multiple epitope dynamics</b>		<b>196</b>
B.1	An invariant of motion	196
B.2	Local dynamics of a multiple epitope equation	197
B.3	The $2 \times 2$ system	200
B.3.1	$\eta = 0$	200
B.3.2	$\eta > 0$	202
B.3.3	The limit of large $\eta$	204
B.4	Intracellular competition between epitopes	207
<b>References</b>		<b>209</b>
<b>Index</b>		<b>233</b>